Pharma and healthcare: sector news on Friday 20 November 2026
Average tone +4.8 (positive) across 3 companies with relevant coverage, from 42 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | +6.3 | 22 | Coverage mainly covered a second US approval for a lung cancer drug from the Nuvalent purchase and Japanese orphan drug status for velzatinib in GIST. |
| AstraZeneca | +8.0 | 19 | Coverage was dominated by the FDA granting priority review to AstraZeneca's sonesitatug vedotin for gastric cancer, which is clearly positive. |
| Convatec | 0.0 | 1 | |
| Haleon | — | 0 | |
| Smith & Nephew | — | 0 |
Strongest stories in the sector
- +10.0 Regulator fast-tracks cancer drug backed by strong survival benefit.
- +10.0 Second US regulatory clearance for a lung cancer therapy gained through acquisition.
- +10.0 Company lifted its organic growth outlook for the year.}, {
- +10.0 Acquired company's drug gains another approval, validating the large purchase.
- +9.7 Accelerated regulatory review granted for gastric cancer therapy.
- +9.5 US regulator expedites review of cancer drug.
- +9.5 US regulator gives faster review to gastric cancer candidate.
- +9.5 Gastric cancer medicine receives accelerated US regulatory review.
- +9.5 Official announcement of accelerated US review for gastric cancer drug.
- +9.3 Quick regulatory review for targeted gastric cancer treatment.
- +9.3 Gastric cancer drug obtains accelerated US regulatory review.
- +9.3 Company announces accelerated US review of its application.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.